Determinants of postembolization syndrome after hepatic chemoembolization

被引:200
作者
Leung, DA
Goin, JE
Sickles, C
Raskay, BJ
Soulen, MC
机构
[1] Hosp Univ Penn, Div Intervent Radiol, Philadelphia, PA 19104 USA
[2] DataMedix Corp, Media, PA USA
[3] Univ Penn, Ctr Canc, Hosp Univ Penn, Philadelphia, PA 19104 USA
关键词
embolization; hepatic arteries; therapeutic blockade; liver neoplasms; therapy;
D O I
10.1016/S1051-0443(07)61911-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: Postembolization syndrome (PES) occurs in the majority of patients undergoing hepatic chemoembolization, and is the major reason for hospitalization after the procedure. The ability to identify which groups of patients are at increased or decreased risk of PES would be useful to better counsel patients, to minimize toxicity, and to plan inpatient versus outpatient therapy. MATERIALS AND METHODS: Seventy hepatic chemoembolization procedures were performed in 29 patients using cytotoxic drugs mixed with Ethiodol and polyvinyl alcohol. The following procedural variables were retrospectively assessed and evaluated for association with PES and length of postprocedural hospitalization: gallbladder embolization, lobe embolized, percentage liver volume embolized, percentage embolized volume occupied by tumor, previous embolization of the same territory, and dose of chemoembolic emulsion. Logistic regression was used to quantify the relative effect of each procedural variable. RESULTS: Gallbladder embolization and dose administered were associated with an increased risk of PES and an extended hospitalization, with odds ratios of 2.8 and 3.0, and 3.0 and 4.6, respectively. Previous embolization was associated with a decreased risk of both PES and extended hospitalization, with odds ratios of 0.5 and 0.4, respectively. There was a statistical trend toward significance for gallbladder embolization (P = .06), dose administered (P = .07), and previous embolization (P = .14). CONCLUSION: Clinically relevant predictors of the severity of PES and length of postprocedural hospitalization may exist. Avoiding embolization of the gallbladder reduces the risk of PES. Re-embolization of previously treated vessels is associated with decreased toxicity and may assist in selecting patients for treatment on an outpatient basis, especially when a reduced dose is required.
引用
收藏
页码:321 / 326
页数:6
相关论文
共 11 条
  • [1] *AM HOSP ASS, 1995, COD CLIN
  • [2] Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization
    Chung, JW
    Park, JH
    Han, JK
    Choi, BI
    Han, MC
    Lee, HS
    Kim, CY
    [J]. RADIOLOGY, 1996, 198 (01) : 33 - 40
  • [3] REGIONAL ANESTHESIA FOR HEPATIC ARTERIAL EMBOLIZATION
    COLDWELL, DM
    LOPER, KA
    [J]. RADIOLOGY, 1989, 172 (03) : 1039 - 1040
  • [4] Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma
    Kim, YH
    Ajani, JA
    Carrasco, CH
    Dumas, P
    Richli, W
    Lawrence, D
    Chuang, V
    Wallace, S
    [J]. CANCER INVESTIGATION, 1999, 17 (07) : 474 - 478
  • [5] Hepatic artery embolization: Factors predisposing to postembolization pain and nausea
    Patel, NH
    Hahn, D
    Rapp, S
    Bergan, K
    Coldwell, DM
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2000, 11 (04) : 453 - 460
  • [6] Razavi MK, 1998, RADIOLOGY, V209P, P412
  • [7] Complications associated with transcatheter arterial embolization for hepatic tumors
    Sakamoto, I
    Aso, N
    Nagaoki, K
    Matsuoka, Y
    Uetani, M
    Ashizawa, K
    Iwanaga, S
    Mori, M
    Morikawa, M
    Fukuda, T
    Hayashi, K
    Matsunaga, N
    [J]. RADIOGRAPHICS, 1998, 18 (03) : 605 - 619
  • [8] Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol and polyvinyl alcohol: Prospective evaluation of response and survival in a US population
    Solomon, B
    Soulen, MC
    Baum, RA
    Haskal, ZJ
    Shlansky-Goldberg, RD
    Cope, C
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1999, 10 (06) : 793 - 798
  • [9] Soulen MC, 2000, APPL RADIOL, V29, P21
  • [10] Tellez C, 1998, CANCER, V82, P1250, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1250::AID-CNCR7>3.0.CO